← Eichor
Study identifier: NCT06755684 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Condition: EGFR · Non-Small Cell Lung Cancer · Locally Advanced Non-Small Cell Lung Cancer  ·  Sponsor: Peng Zhang

PhasePhase 2
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

This description comes directly from the study's public registry record.

Talk to the study team

Peng Zhang  ·  02165115006  ·  zhangpeng1121@tongji.edu.cn

Yue Liu  ·  18831402353@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Pulmonary HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06755684